Background: Ancillary molecular testing has been recommended for thyroid fine-needle aspirates (FNA) with indeterminate cytologic diagnoses. Rosetta Genomics and Interpace Diagnostics have developed assays that can utilize direct smears as the testing substrate.
FNA is the equivocal nature of numerous smears. 7 The subjective aspect of interpretation and wide interobserver variability add additional levels of complexity. 3, 4, 9 Up to 30-40% of cases are borderline and classified as indeterminate. 2, 6, [8] [9] [10] They are incorporated into the following groups: atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS, Bethesda category III); follicular neoplasm/suspicious for follicular neoplasm (FN/SFN, Bethesda category IV); and suspicious for malignancy (SM, Bethesda category V). 5 The study of molecular genetics in disease is a rapidly expanding field. Progress with research has identified genetic alterations associated with thyroid cancer. 2, 4, 11 It has created opportunities to increase the diagnostic accuracy of thyroid FNA and redefine indeterminate aspirates for clinical management. 4, 12 The importance of molecular markers was recently addressed in the 2015 American Thyroid Association (ATA) guidelines. Ancillary molecular testing has been recommended for thyroid fine-needle aspirates with indeterminate cytologic diagnoses. 4, 8, 9, 13 Many thyroid molecular tests employed by clinicians (Afirma and ThyroSeq) require that additional aspirates be procured and submitted in special collection media. 4, 6, 14 Afirma Gene Expression Classifier (Table 1) . 4, 9 However, two companies, Rosetta Genomics and Interpace Diagnostics, have developed microRNA-based assays that can utilize direct smears as the testing substrate. 1, 6 Advancements with next-generation sequencing have allowed the discovery of novel targets for molecular testing, including microRNAs (miRNAs). 10 MicroRNAs are small, noncoding RNA molecules that are intricately involved with regulating cellular function. They play a role in controlling the cell cycle with gene expression, proliferation, and survival. 1, 4, 8, 15 Numerous publications have reported the divergent expression of miRNAs in distinct tumors, including thyroid cancer. 1, 6, 10, 12, 15 RosettaGX Reveal is a relatively new microRNA-based assay, and few articles have been published in the literature. 1, 6 This test evaluates the expression of 24 miRNAs, including not only ones upregulated in papillary thyroid carcinoma but also those that are downregulated. It has the unique feature of being developed for use with routinely prepared cytology smears (Table 1) . 1 The concept of extracting miRNAs from Papanicolaou or Romanowsky-stained slides is cutting edge for thyroid cytopathology. 15 Furthermore, Interpace Diagnostics introduced a multiplatformtesting algorithm to aid in the evaluation of indeterminate aspirates.
ThyGenX is based on the oncogene panel originally marketed as miRInform by Asuragen. 4, 7 It maintains the same 4 DNA point mutations and 3 RNA translocation fusion markers that are highly specific for differentiated thyroid cancer. 10, 12 It has been modified with next-generation sequencing and now can detect >100 genetic alterations across eight genes ( Table 1) . 4 Moreover, ThyraMIR is a molecular test designed to analyze the expression of 10 different microRNAs to further modify the risk of malignancy. 4, 8, 10, 15 In the two-step process at Interpace, ThyGenX is performed monolayer Thin Prep slides, and even formalin-fixed paraffinembedded tissue through their internal validation process (Table 1 ).
Our study is the first to examine the feasibility of using the direct smears as the test samples.
Utilizing direct smears for molecular testing is an exciting advance- 
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A total of 10 thyroid FNAs (7 females, 3 males; ages 25-65) were identified from our 2015 files. The cytologic diagnoses included FLUS (n 5 5), FN/SFN (n 5 4), and SM (n 5 1). All cases had material collected for Afirma GEC at the time of rapid assessment, and the test was performed in 7/10 of the samples (Table 2) .
Seven patients (7/10) had a total thyroidectomy, and three (3/10) underwent a lobectomy (Table 2) . Investigating the circumstances surrounding the clinical decision to operate was beyond the scope of this study. The histologic results included nodular hyperplasia (n 5 1) and follicular adenoma (n 5 6). Malignancies comprised follicular variant of papillary thyroid carcinoma (FVPTC, n 5 1), papillary thyroid carcinoma (PTC, n 5 1), and follicular carcinoma (n 5 1) ( Table 3 ).
All 10 smears passed the preanalytical steps for quality assurance and were evaluated for microRNA (miRNA) expression with RosettaGX
Reveal. Also, each case was interrogated for gene mutations and rearrangements with the oncogene panel ThyGenX. Only 9/10 of the cases were reflexed to the second tier of testing to detect miRNAs with ThyraMIR (Table 3) .
Of the seven cases with benign histology, six FNA smears were classified as benign by RosettaGX, and one case was designated as suspicious. Five cases were classified as negative by both ThyGenX and ThyraMIR. One case was negative by ThyGenX and positive on followup ThyraMIR with a 50-60% risk of malignancy, and one case was Improving the diagnostic yield from thyroid FNA is at the forefront of current research in cytopathology. 2, 12 Close analysis of nuclear detail and cytomorphologic characteristics will never completely eliminate the indeterminate category. 3, 7 Application of immunocytochemical stains also proved inadequate with low specificity and minimal reproducibility. 4, 7 As with many areas in medicine, the focus has shifted to molecular testing and detection of genetic alterations in thyroid cancer. [2] [3] [4] 12 The goal is to increase the number of malignancies accurately diagnosed on FNA and to reduce the extent of potentially avoidable surgeries. 1, 6, 7, 9, 10 The 2015 ATA management guidelines propose the use of molecular studies in indeterminate aspirates to enhance risk stratification and treatment planning. 2, 4, 8, 12, 13 Much of the research surrounds identification of BRAF and RAS point mutations and RET/PTC and PAX8/ PPARg rearrangements. 6, 9, 12, 14 These four genes are well known to be the most common in differentiated thyroid cancer and have implications for diagnosis and prognosis. 4, 7, 11 Nevertheless, there is a subset of tumors that lack these genetic aberrations. (Table   1) . 4, 8 Its high negative predictive value and utility as a "rule-out" test have been widely advertised among cytopathologists, endocrinologists, and surgeons. 4, 9, 10 A drawback to the test is that it calls for two dedicated FNA passes. The decision to collect for Afirma GEC has to be made at the time of rapid assessment. Unless aspirates are immediately stored in preservative and shipped under specific conditions, the test cannot be performed. The specifications from the manufacturers were naturally considered when designing our study. Preanalytic factors can never be completely excluded from having an impact on the data collection. In accordance with analytic validation studies, Rosetta Genomics allows submission of either Diff-Quik-stained or Papanicolaou-stained slides.
In contrast, Interpace can only accept Papanicolaou-stained smears.
We sought to minimize the influence from preanalytic variables by carefully selecting slides of comparable cellularity from each case. One air-dried Diff-Quik-stained slide was shipped to Rosetta, and one Papanicolaou-stained smear was sent to Interpace.
As with other molecular platforms, it is important to recognize that This study demonstrates that these two molecular testing platforms performed equally well using our stained direct smears. Similar to Afirma GEC, the results from Rosetta are released as either benign or suspicious. RosettaGX had one false positive in our sample population. The smear was flagged as suspicious, and it was associated with a follicular adenoma on subsequent thyroidectomy.
In contrast, Interpace uses a two-step algorithm for testing and (Table 3) .
When assessing risk of malignancy, it is evident that our results are based on a low number of cases, and this may bias the figures. We acknowledge this as a potential limitation, but we hope our findings can spark interest for future investigation. Both RosettaGX and ThyGenX/ThyraMIR demonstrated a sensitivity of 100%. This is along the same trajectory as the data described in the literature with a sensitivity of 85% for RosettaGX and 89% for ThyGenX/ThyraMIR. 1, 4, 9, 10 In our analysis, RosettaGX demonstrated a specificity of 86%, which is higher than the industry reported value of 72%. 1 In comparison, ThyGenX/ ThyraMIR showed a specificity of 71%, which is slightly lower than the published value of 85% (Table 4) . 4, 9, 10 Both molecular tests revealed a 100% negative predictive rate.
RosettaGX showed a 75% positive predictive value (PPV) in comparison to 60% for ThyGenX/ThyraMIR (Table 4 ). The data is undoubtedly affected by our small sample size, but it shows promising results. Utilizing stained direct smears is a new and innovative approach to molecular analysis in thyroid cytology. A long-term analysis with RosettaGX and multiplatform ThyGenX/ThyraMIR on a larger sample size is needed to reinforce the strength of these assays with direct smears.
Even if additional material is not requested during the on-site evaluation, there are now more options available for ancillary testing.
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